Evaluation of the AIVARIX in Detecting Signs C 1-2 Classes of CVD
Не применимо
Завершено
NCT05612217
| Заболевание | Chronic Venous Disease, CVD |
|---|
| Фаза | Не применимо |
|---|
| Спонсор | Servier Russia |
|---|
| Статус | Завершено |
|---|
| Участники | 433 участн. |
|---|
| Вмешательство | to estimate Sensitivity and Specificity AIVARIX app in detecting C1 and C2 classes of CVD |
|---|
| Дата начала | 1.12.2022 |
|---|
| Дата завершения | 1.06.2023 |
|---|
| Публикация результатов | 25.09.2024 |
|---|
Кратко
This study is a multicenter observational study, which is carried out in frame of routine clinical practice in Russia. The program will include patients suggestive to chronic venous diseases (CVDs) including but not limited to those with C1 and C2 classes by CEAP classification, who will be seeking professional phlebologists' consultation. Study conduction is scheduled in Russia in 2022-2023. The planned number of patients is 414
Evaluation of Sensitivity (Sn) of the AI-based AIVARIX App in Detecting C1 and C2 Classes of CVD in Patients Who Are Seeking for Professional Advice From a Phlebologist Regarding Symptoms and Signs Suggestive to CVD.
1 month · percentage of of positive cases
| Patients With CVD | 75.19 percentage of of positive cases |
|---|
Evaluation of Specificity (Sp) of the AI-based AIVARIX App in Detecting C1 and C2 Classes of CVD in Patients Who Are Seeking for Professional Advice From a Phlebologist Regarding Symptoms and Signs Suggestive to CVD
1 month · percentage of negative cases
| Patients With CVD | 86.51 percentage of negative cases |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.